Eisai Announces Establishment of New Pharmaceuticals Marketing Subsidiary in Portugal
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical marketing subsidiary, EF-Eisai Farmacêutica, Unipessoal Lda. (Eisai Farmacêutica), in Portugal. Eisai Farmacêutica is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya).
Eisai's new subsidiary in Portugal Eisai Farmacêutica will start marketing activities in Portugal in FY 2007, with the launch of its neurology products including the anti-epileptic drugs Zonegran® and Inovelon® (for which Eisai received positive opinion for Inovelon® marketing authorization from European Committee for Medicinal Products for Human Use on November 16, 2006), as well as the non-opioid severe chronic pain agent Prialt®. In addition, Eisai Farmacêutica plans to start promotion of its leading product Aricept® in Portugal with its co-promotion partner.
Eisai has been rapidly expanding its business operations across Europe by strengthening its sales and marketing presence within the territory. The establishment of Eisai Farmacêutica, which will be the Company's eighth marketing subsidiary in Europe, will accelerate further business operations in Europe together with the Company's own sales channels in 12 countries including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway and Portugal.
Through stable provision of Eisai's products enabled by establishment of the new subsidiary, Eisai is committed to fulfilling the unmet medical needs and increasing the benefit to patients and their families in these countries.
Corporate Communications Department
Eisai Co., Ltd.